Global Radiopharmaceuticals Market Outlook 2020 - Research and Markets
DUBLIN, July 28, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "Global Radiopharmaceuticals Market Outlook 2020" report to their offering.
Radioisotopes are radioactive isotopes having an unstable balance of atomic nucleus. Radioisotopes are produced either by using nuclear research reactor or by using cyclotron. These isotopes emit energy in the form of alpha, beta or gamma when changed to a stable nature. The gamma rays, thus emitted are used in Nuclear medicine, specifically in medical diagnostics. In this field, the radiation is used to provide diagnostic information about a human body's functioning. Radiotherapy is also used to treat some life-threatening diseases like cancer. Also, it has been observed that the increasing use of radioisotopes is one of the major reasons for a fall in deaths caused by cancer across the globe. It is because of this feature that the demand for radioisotopes or otherwise called radiopharmaceuticals is increasing significantly.
The global radiopharmaceuticals market is dominated by the North American region followed by the European region. Owing to the production of Mo-99 by the Canada and continuous research activities in different clinical institutes in USA such as National Cancer Institute, the North American market is headed for a strong growth in the future. Other markets in the Asia-Pacific region are also expected to show a significant growth in the future, with China, India, Japan, South Korea, Brazil, and South Africa being the most promising and potential regions. The major driver of growth in these countries is the domestic production of isotopes by reactors coupled with supportive government initiatives.
The radiopharmaceuticals market can be segmented into diagnostic & therapeutic radiopharmaceuticals. Close to 90% of the global radiopharmaceuticals market is dominated by diagnostic segment wherein SPECT accounts for major market share. The SPECT market is dominated by Tc-99m isotopes and F-18 accounts for majority of share in PET segment.
Global Radiopharmaceuticals Market Outlook 2020 Report Highlight:
- Global Radiopharmaceutical Market Overview
- Global Radiopharmaceuticals Market Dynamics
- FDA & EMA Guidelines for Radiopharmaceuticals
- Global Radiopharmaceuticals Clinical Pipeline Insight by Company, Indication & Phase
- Global Radiopharmaceuticals Clinical Pipeline: 133 Radiopharmaceuticals
- Majority Radiopharmaceuticals in Preclinical Phase: 44 Radiopharmaceuticals
- Marketed Radiopharmaceuticals: 19 Radiopharmaceuticals
Key Topics Covered:
1. Global Radiopharmaceutical Market Overview
1.1 Current Market Scenario
1.2 Diagnostic & Therapeutic Radiopharmaceuticals
1.3 Global Radiopharmaceticals Clinical Pipeline Overview
2. Global Radiopharmaceuticals Market Dynamics
3. Radioisotopes Used in Radiopharmaceuticals
4. EMA Guidelines for Radiopharmaceuticals
4.1 Physico-Chemical, Biological or Microbiological Tests of Medicinal Products
4.2 Toxicological & Pharmacological Tests
4.3 Clinical Documentation
4.4 Radiation Dosimetry
4.5 Labelling & Packaging
5. FDA Guidelines for Radiopharmaceuticals
5.1 Clinical Indication
5.2 General Considerations for Safety Assessments
5.3 Clinical Evaluation of Medical Imaging Agents
6. Canada Guidelines for Radiopharmaceuticals
6.1 Use of Positron Emitting Radiopharmaceuticals (PERs) in Basic Research
6.2 Use of Positron Emitting Radiopharmaceuticals in Basic Research involving Humans
6.3 Stability Testing of Existing Drug Substances and Products
6.4 Good Manufacturing Practices (GMP) for Positron Emitting Radiopharmaceuticals (PERs)
7. Global Radiopharmaceuticals Clinical Pipeline Insight by Company, Indication & Phase
7.1 Unknown
7.2 Research
7.3 Preclinical
7.4 Phase-0
7.5 Phase-I
7.6 Phase-I/II
7.7 Phase-II
7.8 Phase-II/III
7.9 Phase-III
7.10 Preregistration
8. Marketed Radiopharmaceuticals Clinical Insight by Indication
8.1 Florbetapir F 18 (Amyvid)
8.2 Iobenguane I-123 (AdreView)
8.3 Ibritumomab Tiuxetan (Zevalin & Zevamab)
8.4 Radium-223 Chloride (Alpharadin & Xofigo)
8.5 Tc 99m Tilmanocept (Lymphoseek)
8.6 Florbetaben F18 (NeuraCeq)
8.7 Capromab (ProstaScint)
8.8 Pentetreotide (Oktreotid & 111In)
8.9 Iodine I 131 Derlotuximab Biotin (Cotara)
8.10 Tc 99m Besilesomab (Scintimun)
8.11 Samarium 153 lexidronam (Quadramet)
8.12 Technetium Tc 99m Sulfur Colloid Injection
8.13 Tc 99m Apcitide (AcuTect)
8.14 DW 166HC (Milican)
8.15 Tc 99m Sulesomab (LeukoScan)
8.16 Satumomab (OncoScint CR/OV)
8.17 Pentetreotide (OctreoScan & SomatoTher)
8.18 Tc 99m ior cea1
8.19 Tc 99m Nofetumomab Merpentan (VerLuma)
9. Discontinued & Suspended Radiopharmaceuticals by Indication & Phase
9.1 No Development Reported
9.2 Discontinued
9.3 Market Withdrawal
9.4 Suspended
10. Competitive Landscape
10.1 Avid Radiopharmaceuticals
10.2 Actinium Pharmaceuticals
10.3 AREVA Med
10.4 Bayer HealthCare Pharmaceuticals
10.5 Cardinal Health
10.6 Immunomedics
10.7 Lantheus Medical Imaging
10.8 Merck
10.9 Navidea
10.10 Nordion
10.11 Lantheus Medical Imaging
10.12 GE Healthcare
10.13 Ion Beam Applications
10.14 PETNET Solutions (Siemens Healthcare Global)
For more information visit http://www.researchandmarkets.com/research/m5mdlv/global
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Share this article